Metric Deep Dive: Understanding Nektar Therapeutics (NKTR) Through its Ratios

Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

After finishing at $1.14 in the prior trading day, Nektar Therapeutics (NASDAQ: NKTR) closed at $1.09, down -4.39%. In other words, the price has decreased by -$4.39 from its previous closing price. On the day, 1.27 million shares were traded. NKTR stock price reached its highest trading level at $1.19 during the session, while it also had its lowest trading level at $1.06.


Our goal is to gain a better understanding of NKTR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.79 and its Current Ratio is at 6.10. In the meantime, Its Debt-to-Equity ratio is 1.83 whereas as Long-Term Debt/Eq ratio is at 1.68.

Jefferies Upgraded its Underperform to Hold on May 10, 2023, whereas the target price for the stock was revised from $1.50 to $1.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 14 ’24 when CHESS ROBERT sold 19,500 shares for $1.20 per share. The transaction valued at 23,400 led to the insider holds 255,273 shares of the business.

ROBIN HOWARD W sold 16,650 shares of NKTR for $29,138 on May 17 ’24. The President & CEO now owns 863,239 shares after completing the transaction at $1.75 per share. On May 17 ’24, another insider, Zalevsky Jonathan, who serves as the Chief R&D Officer of the company, sold 7,355 shares for $1.75 each. As a result, the insider received 12,871 and left with 257,670 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 209782480 and an Enterprise Value of 142847840. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.22 while its Price-to-Book (P/B) ratio in mrq is 1.58. Its current Enterprise Value per Revenue stands at 1.584 whereas that against EBITDA is -1.138.

Stock Price History:

The Beta on a monthly basis for NKTR is 0.65, which has changed by 0.87931037 over the last 52 weeks, in comparison to a change of 0.2586832 over the same period for the S&P500. Over the past 52 weeks, NKTR has reached a high of $1.93, while it has fallen to a 52-week low of $0.41. The 50-Day Moving Average of the stock is -26.05%, while the 200-Day Moving Average is calculated to be 30.07%.

Shares Statistics:

The stock has traded on average 2.20M shares per day over the past 3-months and 1348250 shares per day over the last 10 days, according to various share statistics. A total of 191.38M shares are outstanding, with a floating share count of 178.72M. Insiders hold about 2.88% of the company’s shares, while institutions hold 59.55% stake in the company. Shares short for NKTR as of 1715731200 were 2647761 with a Short Ratio of 1.25, compared to 1713139200 on 3113324. Therefore, it implies a Short% of Shares Outstanding of 2647761 and a Short% of Float of 1.8499999999999999.

Most Popular